Japanese Journal of Clinical Oncology, Vol 27, Issue 1 26-30, Copyright © 1997 by Foundation for Promotion of Cancer Research
S Samma, Y Kagebayashi, M Yasukawa, Y Fukui, S Ozono, Y Hirao, H Sato and E Okajima
Urinary concentration of pyridinoline and deoxypyridinoline, novel markers
of bone resorption, was measured serially in patients with prostate cancer
as markers of metastatic bone tumor. In 11 patients, five without bone
metastasis and six with bone metastasis, pyridinoline and deoxypyridinoline
were serially monitored for between 6 and 24 months. All patients received
some hormonal therapy with or without radical prostatectomy. Pyridinoline
and deoxypyridinoline were measured by ion-paired high-performance liquid
chromatography and were adjusted according to urinary creatinine
concentration. The sequential changes of pyridinoline and deoxypyridinoline
were compared with those of prostatic specific antigen and alkaline
phosphatase as well as with the findings of bone scintigrams. During the
observation periods, no metastatic bone lesion developed and no significant
changes in pyridinoline and deoxypyridinoline occurred in the five patients
without bone metastasis. In the six patients with bone metastasis, the
levels of prostatic-specific antigen showed relatively rapid decreases
after starting therapy. In contrast, the levels of pyridinoline,
deoxypyridinoline and alkaline phosphatase showed transient increases
followed by gradual decreases in most cases. Correlations were observed
between the changes of pyridinoline and deoxypyridinoline and the findings
of bone scintigrams. The data suggest that serial monitoring of
pyridinoline and deoxypyridinoline could be clinically useful as markers of
metastatic bone tumors and may allow less frequent bone scintigrams during
patient followup.
ORIGINAL ARTICLE
Sequential changes of urinary pyridinoline and deoxypyridinoline as markers of metastatic bone tumor in patients with prostate cancer: a preliminary study
Department of Urology, Nara Kokuho Chuo Hospital, Japan.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. E. Coleman, P. Major, A. Lipton, J. E. Brown, K.-A. Lee, M. Smith, F. Saad, M. Zheng, Y. J. Hei, J. Seaman, et al. Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic Acid J. Clin. Oncol., August 1, 2005; 23(22): 4925 - 4935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. G. Rosano, R. T. Peaston, H. G. Bone, H. W. Woitge, R. M. Francis, and M. J. Seibel Urinary free deoxypyridinoline by chemiluminescence immunoassay: analytical and clinical evaluation Clin. Chem., October 1, 1998; 44(10): 2126 - 2132. [Abstract] [Full Text] [PDF]
|
|